A study released by the National Cancer Institute demonstrated the potential for a risk tool to forecast adverse opioid-related outcomes among cancer survivors.
Brigatinib reduced the risk of disease progression or death in adults with advanced ALK-positive non-small cell lung cancer who had not received a prior ALK inhibitor.
Patients, providers, and healthcare processes benefit from systematically collecting patient-reported outcomes and reviews of their experiences in breast cancer treatment.
